There is increasing interest in the use of cannabinoids for disease and symptom
management, but limited information available regarding their pharmacokinetics and …

Cannabis has been employed medicinally throughout history, but its recent legal prohibition,
biochemical complexity and variability, quality control issues, previous dearth of …

Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective
drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low …

Background A formal single ascending and multiple dose pharmacokinetic (PK) trial of
cannabidiol (CBD) oral solution was required to determine the safety and tolerability of CBD …

Objective To identify potential pharmacokinetic interactions between the pharmaceutical
formulation of cannabidiol (CBD; Epidiolex) and the commonly used antiepileptic drugs …

Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application
in a wide‐variety of contexts; however, its effective dose in different disease states remains …

The interest in cannabis-based products for the treatment of refractory epilepsy has
skyrocketed in recent years. Marijuana and other cannabis products with high content in Δ …

This Perspective of the published essential medicinal chemistry of cannabidiol (CBD)
provides evidence that the popularization of CBD-fortified or CBD-labeled health products …

The phytocannabinoids of Cannabis sativa L. have, since ancient times, been proposed as a
pharmacological alternative for treating various central nervous system (CNS) disorders …

OBJECTIVE To assess the effect of oral cannabidiol (CBD) administration in addition to
conventional antiepileptic treatment on seizure frequency in dogs with idiopathic epilepsy …